EUVIMEDEUVIMED entdecken
Crossref

An industry perspective on the FDA Modernization Act 2.0/3.0: potential next steps for sponsors to reduce animal use in drug development

Sarah A Carratt iD, Christina L Zuch de Zafra, Elias Oziolor, Payal Rana, Nichole R Vansell, Raja Mangipudy, Vishal S Vaidya

Toxicological Sciences · 01.01.2025 · 203 (1) · 28-34

DOI: 10.1093/toxsci/kfae122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Toxicological Sciences, online erschienen am 19.09.2024. Verfasst von Sarah A Carratt und 6 weiteren Autor:innen. Beteiligte Einrichtung: Drug Safety Research and Development, Pfizer Research and Development, Bothell, WA 98021, United States. Hauptthemen laut MEDLINE: United States Food and Drug Administration, Drug Development, Drug Industry. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pharmaceutical developers are encouraged to adopt the best practices of being purposefully thoughtful about the use of animals, seeking alternatives wherever possible. They should engage with health authorities to increase their familiarity with the methods, study designs, data outputs, and the context of use for new approach methodologies (NAMs). Although current state of technology does not yet provide adequate models to fully replace in vivo studies, many models are sufficiently good for an augmented approach that will enhance our understanding of in vitro to in vivo correlations and advance the long-term goal of reducing animal use through innovative NAMs. The goal of future nonclinical safety packages is to advance the utilization of such enabling technologies toward appropriate human risk characterization. Establishing confidence in NAMs is a critical first step. For example, sponsors may include both “traditional” and NAM-based nonclinical safety data in regulatory submissions to establish confidence with health authorities. In addition, regulators should create a “safe harbor” for hybrid nonclinical data packages to facilitate iterative learning, refinement, and implementation of NAM-based safety assessment strategies. Sponsors are urged to contribute to NAMs evolution through consortia participation, peer-reviewed publications, and documenting animal reduction in studies/programs, accelerating the eventual elimination of animal use in pharmaceutical development, as envisioned in the FDA Modernization Act 3.0.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

United States Food and Drug AdministrationDrug DevelopmentDrug IndustryAnimalsUnited StatesHumansAnimal Testing Alternatives

Stichwörter der Autor:innen

FDA Modernization Actnew approach methodologiesregulatory toxicologysafety assessment

Autor:innen und Institutionen

  • Drug Safety Research and Development, Pfizer Research and Development, Bothell, WA 98021, United States.
  • Drug Safety Research and Development, Pfizer Research and Development, San Francisco, CA 94080, United States.
  • Drug Safety Research and Development, Pfizer Research and Development, Groton, CT 06340, United States.
  • Drug Safety Research and Development, Pfizer Research and Development, Cambridge, MA 02138, United States.

ORCID-Profile: Sarah A Carratt

Zitieren

APA

Carratt, S. A., Zuch de Zafra, C. L., Oziolor, E., Rana, P., Vansell, N. R., Mangipudy, R., & Vaidya, V. S. (2025). An industry perspective on the FDA Modernization Act 2.0/3.0: potential next steps for sponsors to reduce animal use in drug development. Toxicological Sciences, 203(1), 28-34. https://doi.org/10.1093/toxsci/kfae122

Vancouver

Carratt SA, Zuch de Zafra CL, Oziolor E, Rana P, Vansell NR, Mangipudy R, et al. An industry perspective on the FDA Modernization Act 2.0/3.0: potential next steps for sponsors to reduce animal use in drug development. Toxicological Sciences. 2025;203(1):28-34. doi:10.1093/toxsci/kfae122

BibTeX
@article{Carratt2025,
  author = {Carratt, Sarah A and Zuch de Zafra, Christina L and Oziolor, Elias and Rana, Payal and Vansell, Nichole R and Mangipudy, Raja and Vaidya, Vishal S},
  title = {An industry perspective on the FDA Modernization Act 2.0/3.0: potential next steps for sponsors to reduce animal use in drug development},
  journal = {Toxicological Sciences},
  year = {2025},
  volume = {203},
  number = {1},
  pages = {28--34},
  doi = {10.1093/toxsci/kfae122}
}
Kostenlos starten →